Advertisement

Experientia

, Volume 34, Issue 3, pp 382–384 | Cite as

Inhibition of noradrenaline release from sympathetic nerves by pentobarbital

  • M. Göthert
  • J. -M. Rieckesmann
Specialia

Summary

Pentobarbital concentrations of 10–100 μM selectively inhibited the noradrenaline release evoked by activation of the nicotinic receptors on the terminals sympathetic nerves of the rabbit heart. Higher concentrations also decreased the noradrenaline release induced by KCl or by electrical stimulation of the nerve axons.

Keywords

Noradrenaline Electrical Stimulation Pentobarbital Sympathetic Nerve Nicotinic Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 3.
    M. P. Blaustein, J. Gen. Physiol.51, 293 (1968).CrossRefPubMedGoogle Scholar
  2. 4.
    P. Seeman, Pharmac. Rev.24, 583 (1972).Google Scholar
  3. 5.
    M. P. Blaustein and A. Christie Ector, Molec. Pharmac.11, 369 (1975).Google Scholar
  4. 6.
    M. P. Blaustein, J. Pharmac. exp. Ther.196, 80 (1976).Google Scholar
  5. 7.
    M. Göthert, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.286, 125 (1974).CrossRefGoogle Scholar
  6. 8.
    S. Huković and E. Muscholl, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.244, 81 (1962).CrossRefGoogle Scholar
  7. 9.
    R. Lindmar and E. Muscholl, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.247, 469 (1964).CrossRefGoogle Scholar
  8. 10.
    R. Lindmar and K. Löffelholz, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.284, 63 (1974).CrossRefGoogle Scholar
  9. 11.
    E. Muscholl, in: New Aspects of Storage and Release Mechanisms of Catecholamines, p. 168. Ed. H. J. Schümann and G. Kroneberg, Springer, Berlin 1970.Google Scholar
  10. 12.
    H. W. Kosterlitz and G. M. Lees, in: Handbook of Experimental Pharmacology, Vol. 33, p. 762. Ed. H. Blaschko and E. Muscholl, Springer, Berlin 1972.Google Scholar
  11. 13.
    K. Starke, Rev. Physiol. Biochem. Pharmac.77, 1 (1977).Google Scholar
  12. 14.
    R. Lindmar, K. Löffelholz and E. Muscholl, Experientia23, 933 (1967).PubMedGoogle Scholar
  13. 15.
    G. Haeusler, H. Thoenen, W. Haefely and A. Huerlimann, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.263, 217 (1969).CrossRefGoogle Scholar
  14. 16.
    A. D. Smith and H. Winkler, in: Handbook of Experimental Pharmacology, Vol. 33, p. 538. Ed. H. Blaschko and E. Muscholl, Springer, Berlin 1972.Google Scholar
  15. 17.
    E. De Robertis, Rev. Physiol. Biochem. Pharmac.73, 9 (1975).Google Scholar
  16. 18.
    N. Barth, M. Manns and E. Muscholl, Naunyn-Schmiedebergs Arch. Pharmak. exp. Path.288 215 (1975).CrossRefGoogle Scholar
  17. 19.
    J. M. Van Rossum, Archs. int. Pharmacodyn.143, 299 (1963).Google Scholar

Copyright information

© Birkhäuser Verlag 1978

Authors and Affiliations

  • M. Göthert
    • 1
  • J. -M. Rieckesmann
    • 1
  1. 1.Pharmakologisches Institut der Universität HamburgHamburg 20(Federal Republic of Germany)

Personalised recommendations